Hussman Strategic Advisors Inc. Purchases Shares of 16,800 PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Hussman Strategic Advisors Inc. purchased a new position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,800 shares of the company’s stock, valued at approximately $1,353,000.

Other large investors have also made changes to their positions in the company. Values First Advisors Inc. acquired a new stake in PROCEPT BioRobotics during the 3rd quarter valued at approximately $27,000. Raleigh Capital Management Inc. bought a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at approximately $32,000. Wilmington Savings Fund Society FSB purchased a new position in PROCEPT BioRobotics during the 3rd quarter valued at about $64,000. Canton Hathaway LLC bought a new stake in PROCEPT BioRobotics during the third quarter valued at $66,000. Finally, Nisa Investment Advisors LLC grew its position in PROCEPT BioRobotics by 178.3% in the third quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company’s stock worth $89,000 after acquiring an additional 713 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics Stock Up 0.4 %

Shares of PRCT stock opened at $67.21 on Thursday. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. The stock has a 50 day moving average of $77.56 and a 200 day moving average of $79.77. PROCEPT BioRobotics Co. has a twelve month low of $45.20 and a twelve month high of $103.81.

Insider Buying and Selling

In other news, EVP Alaleh Nouri sold 28,092 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total value of $2,728,575.96. Following the completion of the sale, the executive vice president now owns 52,472 shares of the company’s stock, valued at $5,096,605.36. This represents a 34.87 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Reza Zadno sold 26,423 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $97.22, for a total value of $2,568,844.06. Following the completion of the transaction, the chief executive officer now directly owns 152,762 shares in the company, valued at approximately $14,851,521.64. This trade represents a 14.75 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 80,935 shares of company stock valued at $7,882,089. 17.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

PRCT has been the subject of a number of recent analyst reports. Morgan Stanley assumed coverage on shares of PROCEPT BioRobotics in a report on Monday, December 2nd. They set an “overweight” rating and a $105.00 price target for the company. Wells Fargo & Company reissued an “overweight” rating and issued a $112.00 target price on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Jefferies Financial Group began coverage on shares of PROCEPT BioRobotics in a report on Thursday, November 14th. They issued a “hold” rating and a $95.00 target price for the company. Finally, Truist Financial reaffirmed a “buy” rating and set a $105.00 price objective (up from $95.00) on shares of PROCEPT BioRobotics in a report on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $97.86.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).